Table 1 Patient demographics of the overall FLAURA population and the resistance analysis subseta

From: Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer

Characteristic

Osimertinib

Comparator EGFR-TKI

 

Overall population (n = 279)

Resistance analysis subset (n = 109)

Overall population (n = 277)

Resistance analysis subset (n = 145)

Age: median (range), years

64 (26–85)

62 (26–83)

64 (35–93)

63 (35–93)

Sex: male/female, n (%)

101 (36)/178 (64)

43 (39)/66 (61)

105 (38)/172 (62)

48 (33)/97 (67)

Race: Asian/Non-Asian, n (%)

174 (62)/105 (38)

71 (65)/37 (34)b

173 (62)/104 (38)

92 (63)/53 (37)

WHO performance status: 0/1/2, n (%)

112 (40)/167 (60) /0

42 (39)/67 (61)/0

116 (42)/160 (58) /1 (<1)

56 (39)/89 (61)/0

EGFR mutations: Ex19del/L858R/no mutation detected, invalid test, or no or inadequate sample, n (%)

158 (57)/97 (35) / 24 (9)

59 (54)/39 (36)/11 (10)

155 (56)/90 (32) / 32 (12)

90 (62)/44 (30)/11 (8)

Histology: adenocarcinoma/other, n (%)

275 (99)/4 (1)

108 (99)/1 (1)

272 (98)/5 (2)

142 (98)/3 (2)

  1. EGFR epidermal growth factor receptor, EGFRm EGFR mutation-positive, EGFR-TKI epidermal growth factor receptor tyrosine kinase inhibitors, Ex19del Exon 19 deletion, WHO World Health Organization.
  2. aSubset of patients with detectable baseline plasma EGFRm who progressed or discontinued treatment up to March 2019.
  3. bOne patient in the resistance analysis subset of the osimertinib arm had missing racial data. In the overall population, five patients (two in the osimertinib arm and three in the comparator EGFR-TKI arm) had large-cell carcinoma; three patients (one in the osimertinib arm and two in the comparator EGFR-TKI arm) had adenosquamous carcinoma; and one patient (in the osimertinib arm) had a carcinoid tumor.
Back to article page